A5063258446- Antibiotic Resistance in Bacteria
- Carbohydrate Chemistry and Synthesis
- Glycosylation and Glycoproteins Research
- Antimicrobial Peptides and Activities
- Chemical Synthesis and Analysis
- Antibiotics Pharmacokinetics and Efficacy
- Antimicrobial Resistance in Staphylococcus
- Pneumonia and Respiratory Infections
- Antibiotic Use and Resistance
- Antimicrobial agents and applications
- Pharmaceutical and Antibiotic Environmental Impacts
- Bacterial biofilms and quorum sensing
- Polyamine Metabolism and Applications
- Click Chemistry and Applications
- Cancer therapeutics and mechanisms
- Cancer Research and Treatments
- Biochemical and Structural Characterization
- Immune Response and Inflammation
- Advanced biosensing and bioanalysis techniques
- RNA Interference and Gene Delivery
- Cancer-related Molecular Pathways
- PI3K/AKT/mTOR signaling in cancer
- Phenothiazines and Benzothiazines Synthesis and Activities
- Bacterial Genetics and Biotechnology
- Bacteriophages and microbial interactions
University of Manitoba
2015-2024
Health Sciences Centre
2009-2022
University of Winnipeg
2016-2019
Manitoba Health
2010-2013
University of Lethbridge
2009-2010
University of Alberta
1997-2006
Noguchi Institute
1999-2002
University of Freiburg
1995
Brock University
1991
ABSTRACT A total of 5,282 bacterial isolates obtained between 1 January and 31 December 2008, inclusive, from patients in 10 hospitals across Canada as part the Canadian Ward Surveillance Study (CANWARD 2008) underwent susceptibility testing. The most common organisms, representing 78.8% all clinical specimens, were follows: Escherichia coli (21.4%), methicillin-susceptible Staphylococcus aureus (MSSA; 13.9%), Streptococcus pneumoniae (10.3%), Pseudomonas aeruginosa (7.1%), Klebsiella...
Oritavancin is a semisynthetic lipoglycopeptide analogue of vancomycin that contains the heptapeptide core common to all glycopeptides. It differs from by presence hydrophobic N-4-(4-chlorophenyl)benzyl (also referred as 4'-chlorobiphenylmethyl) substituent on disaccharide sugar, addition 4-epi-vancosamine monosaccharide amino acid residue in ring 6, and replacement vancosamine moiety 4-epi-vancosamine. One mechanism action oritavancin inhibition transglycosylation (important peptidoglycan...
The purpose of the CANWARD study was to assess antimicrobial activity a variety available agents against 22 746 pathogens isolated from patients in Canadian hospitals between 2007 and 2011. Between 2011, 27 123 were collected tertiary-care centres across Canada; underwent susceptibility testing using CLSI broth microdilution methods. Patient demographic data also collected. Of isolates collected, 45.2%, 29.6%, 14.8% 10.4% blood, respiratory, urine wound specimens, respectively. demographics...
The use of adjuvants that rescue antibiotics against multidrug-resistant (MDR) pathogens is a promising combination strategy for overcoming bacterial resistance. While the β-lactam and β-lactamase inhibitors has been successful in restoring antibacterial efficacy MDR bacteria, to restore fluoroquinolone Gram-negative challenging. We describe tobramycin-ciprofloxacin hybrid activity extremely drug-resistant Pseudomonas aeruginosa isolates vitro enhance vivo. Structure-activity studies reveal...
Chromosomally encoded low membrane permeability and highly efficient efflux systems are major mechanisms by which Pseudomonas aeruginosa evades antibiotic actions. Our previous reports have shown that amphiphilic tobramycin-fluoroquinolone hybrids can enhance efficacy of fluoroquinolone antibiotics against multidrug-resistant (MDR) P. isolates. Herein, we report on a novel class tobramycin-lysine conjugates containing an optimized tobramycin-C12 tether sensitize Gram-negative bacteria to...
There is an urgent need for new therapies to overcome antimicrobial resistance especially in Gram-negative bacilli (GNB). Repurposing old U.S.
Drug efflux mechanisms interact synergistically with the outer membrane permeability barrier of Gram-negative bacteria, leading to intrinsic resistance that presents a major challenge for antibiotic drug development. Efflux pump inhibitors (EPIs) which block antibiotics synergize antibiotics, but clinical development EPI/antibiotic combination therapy treat multidrug-resistant (MDR) infections has been challenging. This is in part caused by inefficiency current EPIs penetrate and resist...
Therapeutic interventions to treat multidrug-resistant (MDR) Pseudomonas aeruginosa infections are severely limited and often require the use of colistin as drug last resort. The major challenges impeding development novel antipseudomonal agents lack cell penetration extensive efflux. We have discovered a tobramycin–moxifloxacin hybrid core structure which enhances outer membrane permeability reduces efflux by dissipating proton motive force cytoplasmic in P. aeruginosa. optimized protects...